Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Genetic Technologies Ltd. (NASDAQ: GENE).

Full DD Report for GENE

You must become a subscriber to view this report.


Recent News from (NASDAQ: GENE)

Genetic Technologies Announces Grant from NHMRC Awarded to University of Melbourne to Substantially Improve Breast Cancer Risk Prediction and Increase Accessibility
MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC...
Source: GlobeNewswire
Date: May, 01 2018 05:30
Genetic Technologies announces collaborative research with the University of Melbourne to broaden the applicability of the BREVAGenplus breast cancer risk assessment test
Genetic Technologies (NASDAQ: GENE ) executes a research and services agreement with The University of Melbourne for the further development and enhancement of the BREVAGen plus breast cancer risk assessment test. More news on: GENETIC TECHNOLOGIES LTD, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: March, 16 2018 07:08
Genetic Technologies Limited Announces Further Collaborative Research with The University of Melbourne to Broaden the Applicability of the BREVAGenplus® Breast Cancer Risk Assessment Test
MELBOURNE, Australia, March 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today the execution of a researc...
Source: GlobeNewswire
Date: March, 16 2018 05:00
Shivom Partnership With Genetic Technologies Will Enable Better Cancer Prediction and Prevention Through Mass Genomic Data Analysis
MUNICH , March 6, 2018 /PRNewswire/ -- Blockchain Genomics Pioneer Joins Forces with Nasdaq-Listed Molecular Diagnostics Company To Accelerate Cancer Detection Through ' Critical Mass ' of Genomics Data   Shivom , the blockchain-powered global 'Unique ID' genomic datab...
Source: PR Newswire
Date: March, 06 2018 09:14
Genetic Tech to team up with Project Shivom to create large genetic database
Genetic Technologies (NASDAQ: GENE ) inks a non-binding term sheet with Project Shivom operator Omix Ventures Private Limited aimed at including GENE in creating the world's largest genetic database. More news on: GENETIC TECHNOLOGIES LTD, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 06 2018 06:54
Genetic Technologies Limited: Project Shivom Strategic Alliance
MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG)  (NASDAQ:GENE) (“ Company ”, “ GTG ”) a diversified molecular diagnostics company; provider of BREVAGen plus ®, a first-in-class, clinically validated risk...
Source: GlobeNewswire
Date: March, 06 2018 05:30
Genetic Tech inks non-binding term sheet with Blockchain Global
Genetic Technologies (NASDAQ: GENE ) has entered into a non-binding term sheet with Blockchain Global Limited aimed at providing a framework for continued discussions about how to potentially apply blockchain to the medical arena. More news on: GENETIC TECHNOLOGIES LTD, Healthcare stocks...
Source: SeekingAlpha
Date: February, 15 2018 06:56
Genetic Technologies Announces Strategic Alliance and Capital Raising
MELBOURNE, Australia, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“ Company ”, “ GTG ”) a molecular diagnostics company and provider of BREVAGen plus ®, a first-in-class, clinically validated risk assessment test f...
Source: GlobeNewswire
Date: February, 15 2018 05:00
Genetic Technologies Limited: Update on Strategic Alliance
MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”), wishes to advise that the Company is presently in discussions with the ASX regarding the possible application of ASX Listing Rule 11.1...
Source: GlobeNewswire
Date: February, 12 2018 05:00
Change of Chief Executive Officer
MELBOURNE, Australia, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”), advises that the Board and Mr Eutillio Buccilli have today agreed that  Mr Buccilli step down as Chief Executive O...
Source: GlobeNewswire
Date: February, 06 2018 05:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-151.091.09521.111.0634,938
2018-08-141.101.07991.12761.0765,028
2018-08-131.151.081.151.0857,870
2018-08-101.141.131.16651.1229,064
2018-08-091.141.111.14241.1060,111

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-153,9716,80158.3885Short
2018-08-1427,53635,32277.9571Short
2018-08-132,1008,40524.9851Cover
2018-08-105,5926,70583.4004Short
2018-08-093,22715,08821.3879Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GENE.


About Genetic Technologies Ltd. (NASDAQ: GENE)

Logo for Genetic Technologies Ltd. (NASDAQ: GENE)

Not available

 

Contact Information

 

 

Current Management

  • Thomas Howitt / CFO

Current Share Structure

  • Market Cap: $134,211 - 05/16/2018
  • Issue and Outstanding: 16,235,218 - 06/30/2017

 


Recent Filings from (NASDAQ: GENE)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 06 2018

 

 


Daily Technical Chart for (NASDAQ: GENE)

Daily Technical Chart for (NASDAQ: GENE)


Stay tuned for daily updates and more on (NASDAQ: GENE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GENE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GENE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GENE and does not buy, sell, or trade any shares of GENE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/